Kang Rui, Chen Ruochan, Zhang Qiuhong, Hou Wen, Wu Sha, Cao Lizhi, Huang Jin, Yu Yan, Fan Xue-Gong, Yan Zhengwen, Sun Xiaofang, Wang Haichao, Wang Qingde, Tsung Allan, Billiar Timothy R, Zeh Herbert J, Lotze Michael T, Tang Daolin
Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Mol Aspects Med. 2014 Dec;40:1-116. doi: 10.1016/j.mam.2014.05.001. Epub 2014 Jul 8.
Complex genetic and physiological variations as well as environmental factors that drive emergence of chromosomal instability, development of unscheduled cell death, skewed differentiation, and altered metabolism are central to the pathogenesis of human diseases and disorders. Understanding the molecular bases for these processes is important for the development of new diagnostic biomarkers, and for identifying new therapeutic targets. In 1973, a group of non-histone nuclear proteins with high electrophoretic mobility was discovered and termed high-mobility group (HMG) proteins. The HMG proteins include three superfamilies termed HMGB, HMGN, and HMGA. High-mobility group box 1 (HMGB1), the most abundant and well-studied HMG protein, senses and coordinates the cellular stress response and plays a critical role not only inside of the cell as a DNA chaperone, chromosome guardian, autophagy sustainer, and protector from apoptotic cell death, but also outside the cell as the prototypic damage associated molecular pattern molecule (DAMP). This DAMP, in conjunction with other factors, thus has cytokine, chemokine, and growth factor activity, orchestrating the inflammatory and immune response. All of these characteristics make HMGB1 a critical molecular target in multiple human diseases including infectious diseases, ischemia, immune disorders, neurodegenerative diseases, metabolic disorders, and cancer. Indeed, a number of emergent strategies have been used to inhibit HMGB1 expression, release, and activity in vitro and in vivo. These include antibodies, peptide inhibitors, RNAi, anti-coagulants, endogenous hormones, various chemical compounds, HMGB1-receptor and signaling pathway inhibition, artificial DNAs, physical strategies including vagus nerve stimulation and other surgical approaches. Future work further investigating the details of HMGB1 localization, structure, post-translational modification, and identification of additional partners will undoubtedly uncover additional secrets regarding HMGB1's multiple functions.
复杂的遗传和生理变异以及驱动染色体不稳定出现、非程序性细胞死亡发展、分化异常和代谢改变的环境因素,是人类疾病和病症发病机制的核心。了解这些过程的分子基础对于开发新的诊断生物标志物以及识别新的治疗靶点至关重要。1973年,一组具有高电泳迁移率的非组蛋白核蛋白被发现,并被称为高迁移率族(HMG)蛋白。HMG蛋白包括三个超家族,即HMGB、HMGN和HMGA。高迁移率族框1(HMGB1)是最丰富且研究最深入的HMG蛋白,它感知并协调细胞应激反应,不仅在细胞内作为DNA伴侣、染色体守护者、自噬维持者以及凋亡细胞死亡的保护者发挥关键作用,而且在细胞外作为典型的损伤相关分子模式分子(DAMP)发挥作用。这种DAMP与其他因素共同作用,具有细胞因子、趋化因子和生长因子活性,从而协调炎症和免疫反应。所有这些特性使HMGB1成为多种人类疾病(包括传染病、缺血、免疫紊乱、神经退行性疾病、代谢紊乱和癌症)中的关键分子靶点。事实上,已经采用了许多新出现的策略在体外和体内抑制HMGB1的表达、释放和活性。这些策略包括抗体、肽抑制剂、RNA干扰、抗凝血剂、内源性激素、各种化合物、HMGB1受体和信号通路抑制、人工DNA、包括迷走神经刺激和其他手术方法在内的物理策略。未来进一步研究HMGB1定位、结构、翻译后修饰细节以及鉴定其他相互作用分子的工作,无疑将揭示有关HMGB1多种功能的更多秘密。